hVIVO’s order book has more than doubled to £65 million, prompting Shore Capital to reiterate its Buy rating and 25p target price.
hVIVO Orderbook More Than Doubles as Commercial Momentum Rebuilds
hVIVO said its orderbook has more than doubled in the first half of 2026, supported by strong commercial momentum and higher proposal activity.
Roaring Waters Capital Raises Poolbeg Pharma Stake to 6.55%
Roaring Waters Capital has increased its holding in Poolbeg Pharma, lifting its voting rights to 6.55%. The investor previously held 5.74% of Poolbeg’s voting rights.
Poolbeg Pharma Advances POLB 001 Patent Protection in Israel
Poolbeg Pharma (AIM: POLB) has received a Notice of Allowance from the Israeli Patent Office for its POLB 001 patent application covering cancer immunotherapy-induced Cytokine Release Syndrome.
Poolbeg Pharma Raises £3.5m as Cathal Friel Invests £250,000
Poolbeg Pharma Plc (AIM: POLB) has raised £3.5 million before expenses through the placing of 58,333,328 new shares at 6p each.
First patient dosed in POLB 001 TOPICAL trial
First Patient Dosed in the POLB 001 TOPICAL Clinical Trial Interim data remains on track for summer 2026 and partnering discussions continue to advance with multiple companies
South African approval boosts POLB intellectual property
POLB 001 patent granted in South Africa for the treatment or prevention of hypercytokinemia and severe influenza Patent decision strengthens Poolbeg’s intellectual property portfolio
Poolbeg Pharma (AIM: POLB) European patent granted for POLB 001 in CRS
Decision to grant European Patent received for POLB 001 in cancer immunotherapy-induced CRS Major milestone will provide IP protection in key European markets, strengthening global patent portfolio
Poolbeg Pharma PLC (AIM: POLB) Preclinical data posters presented at EHA Congress
Two posters with POLB 001 preclinical data presented at the European Hematology Association Congress
Poolbeg Pharma (AIM: POLB) Pre-IND Meeting with the FDA for POLB 001
FDA feedback supports Poolbeg’s proposed development pathway for POLB 001, providing further clarity for ongoing partnering discussions
POLB 001 poster to be presented at EHA 2026 Congress
Poolbeg Pharma plc is set to present new data on its drug candidate POLB 001 at the upcoming European Hematology Association Congress 2026, highlighting the treatment’s potential to prevent cancer
POLB 001 cancer immunotherapy-induced CRS patent granted in Canada
Further strengthening of Poolbeg’s global intellectual property portfolio